Trisenox arsenic trioxide: Phase II; marketed to treat refractory acute promyelocytic leukemia (APL)

In an ongoing U.S. Phase II in 24 patients, 33% (8/24) had 25%-50% reduction in M protein

Read the full 173 word article

How to gain access

Continue reading with a
two-week free trial.